Trump Administration Seeks Dismissal of Lawsuit Addressing Abortion Pill Mifepristone

The administration under President Trump has requested that a federal court reject a lawsuit that challenges the FDA's decision to broaden access to mifepristone, a medication used in abortion procedures.

Attorneys from the Justice Department submitted arguments to a federal court in Amarillo, Texas, asserting that the states of Missouri, Idaho, and Kansas have no grounds to bring their case in that jurisdiction. This request follows an earlier one from the Biden administration in a significant legal dispute over mifepristone before Judge Matthew Kacsmaryk.

"Essentially, states cannot maintain a claim where the initial plaintiffs were found to have no legal standing, voluntarily withdrew their cases, and the states have no relevant ties to this court,” declared lawyers from the Trump administration. They suggested that while the states could pursue these claims in an appropriate jurisdiction, their current lawsuit should be dismissed or moved according to venue requirements.

Initially, the legal challenge against mifepristone was brought by anti-abortion medical groups in November 2022, aiming to reverse FDA modifications that relaxed restrictions on the drug. However, the Supreme Court dismissed this challenge, ruling the plaintiffs lacked legal standing.

However, the attorneys general from Missouri, Idaho, and Kansas sought to continue the case. They argued that programs introduced by the FDA starting in 2016 were unlawful. These changes involved extending the permissible use of mifepristone to ten weeks of pregnancy, expanding who can prescribe it, and permitting its distribution via mail.

The Justice Department argued before Judge Kacsmaryk, appointed by Trump, that the states' claims are unrelated to Texas's Northern District and even if brought forward there, the lawsuit would not proceed due to improper venue.

"No matter the validity of the states' arguments, they cannot proceed in this jurisdiction," administration lawyers noted, insisting their complaint should be dismissed or transferred.

Additionally, the Justice Department contended that these states lacked the legal standing necessary to sue and had exceeded the six-year time limit to contest the FDA's 2016 decisions, with the FDA first approving mifepristone back in 2000 and modifying its guidelines since.

The Ongoing Discussion on Abortion

In 2023, medication abortions accounted for over half of abortion procedures in the U.S., revealed a study by the Guttmacher Institute. Many states, twenty-eight to be precise, impose restrictions on mifepristone, with four prohibiting its sale through the mail.